Malutiple-institutional observational surveillance of Pembrolizumab as a first line treatment for non-small cell lung cancer
Not Applicable
Recruiting
- Conditions
- non small cell lung cancer
- Registration Number
- JPRN-UMIN000032470
- Lead Sponsor
- Osaka International Cancer Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients who have previously received pembrolizumab in a clinical trial will be excluded 2)Pretreated chemotherapy
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To investigate whether obsertive analysis of nivolumab therapy in the real clinical setting reproduces the RR shown by primary analysis of the KeyNote-024 trial.
- Secondary Outcome Measures
Name Time Method